CellGenix

Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world. Sartorius CellGenix has more than two and a half decades of in-house expertise in GMP manufacturing and development of products (for dendritic cells, HSC, cord blood cells and chondrocytes) in the field of cell and gene therapy and regenerative medicine. Sartorius CellGenix’ current Quality Management (QM) system was established for manufacturing of recombinant protein investigational products (patient specific idiotype vaccines and recombinant tumor vaccines) in compliance with GMP under manufacturing authorization from German regulatory authorities. Our mission is to enable and accelerate safe and efficient transition of cell, gene and tissue engineered products from preclinical to post-approval clinical applications for the benefit of patients worldwide. Before joining CellGenix Daniel was responsible as CBO for the global sales and marketing organization at PromoCell GmbH, a premier manufacturer for primary cells and media. Ori Biotech and Sartorius CellGenix collaborate in order to promote innovation within closed-system, cell and gene therapy manufacturing.